The double-edged sword of autoimmunity: Lessons from multiple sclerosis

Toxins

Volumn 2, Issue 4, 2010, Pages 856-877

  Hestvik, Anne Lise K ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Autoimmunity; B cells; Glatiramer acetate; Multiple sclerosis; References and notes; T cells

Indexed keywords

GLATIRAMER; MYELIN BASIC PROTEIN; NATALIZUMAB; PLACEBO; RITUXIMAB;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; B LYMPHOCYTE; BLOOD BRAIN BARRIER; CELL MIGRATION; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CROSS REACTION; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOSURVEILLANCE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NEUROTROPISM; NONHUMAN; PREVALENCE; REVIEW; RISK FACTOR; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNITY; BLOOD-BRAIN BARRIER; CELL MOVEMENT; CENTRAL NERVOUS SYSTEM; HUMANS; MULTIPLE SCLEROSIS; PEPTIDES;

ANIMALIA;

EID: 78651261809     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins2040856     Document Type: Review

References (150)

1. Goodnow, C.C.; Sprent, J.; Fazekas de St, G.B.; Vinuesa, C.G. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005, 435, 590-597.
2. Krogsgaard, M.; Juang, J.; Davis, M.M. A role for self in T-cell activation. Semin. Immunol. 2007, 19, 236-244.
3. Jerne, N.K. Towards a network theory of the immune system. Ann. Immunol. (Paris) 1974, 125C, 373-389.
4. DeJong, B.A.; Smith, M.E. A role for complement in phagocytosis of myelin. Neurochem. Res. 1997, 22, 491-498.
5. Harding, F.A.; McArthur, J.G.; Gross, J.A.; Raulet, D.H.; Allison, J.P. CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992, 356, 607-609.
6. Gee, J.M.; Kalil, A.; Shea, C.; Becker, K.J. Lymphocytes: potential mediators of postischemic injury and neuroprotection. Stroke 2007, 38, 783-788.
7. Liesz, A.; Suri-Payer, E.; Veltkamp, C.; Doerr, H.; Sommer, C.; Rivest, S.; Giese, T.; Veltkamp, R. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat. Med. 2009, 15, 192-199.
8. Moalem, G.; Leibowitz-Amit, R.; Yoles, E.; Mor, F.; Cohen, I.R.; Schwartz, M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. 1999, 5, 49-55.
9. Hauben, E.; Butovsky, O.; Nevo, U.; Yoles, E.; Moalem, G.; Agranov, E.; Mor, F.; Leibowitz-Amit, R.; Pevsner, E.; Akselrod, S.; Neeman, M.; Cohen, I.R.; Schwartz, M. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J. Neurosci. 2000, 20, 6421-6430.
10. Kipnis, J.; Mizrahi, T.; Hauben, E.; Shaked, I.; Shevach, E.; Schwartz, M. Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system. Proc. Natl. Acad. Sci. USA2002,99, 15620-15625.
11. Cameron, H.A.; McKay, R.D. Adult neurogenesis produces a large pool of new granule cells in the dentate gyrus. J. Comp Neurol. 2001, 435, 406-417.
12. varez-Buylla, A.; Garcia-Verdugo, J.M. Neurogenesis in adult subventricular zone. J. Neurosci. 2002, 22, 629-634.
13. Ziv, Y.; Ron, N.; Butovsky, O.; Landa, G.; Sudai, E.; Greenberg, N.; Cohen, H.; Kipnis, J.; Schwartz, M. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat. Neurosci. 2006, 9, 268-275.
14. Rapalino, O.; Lazarov-Spiegler, O.; Agranov, E.; Velan, G.J.; Yoles, E.; Fraidakis, M.; Solomon, A.; Gepstein, R.; Katz, A.; Belkin, M.; Hadani, M.; Schwartz, M. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat. Med. 1998, 4, 814-821.
15. Butovsky, O.; Hauben, E.; Schwartz, M. Morphological aspects of spinal cord autoimmune neuroprotection: colocalization of T cells with B7--2 (CD86) and prevention of cyst formation. FASEB J. 2001, 15, 1065-1067.
16. Butovsky, O.; Ziv, Y.; Schwartz, A.; Landa, G.; Talpalar, A.E.; Pluchino, S.; Martino, G.; Schwartz, M. Microglia activated by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Mol. Cell Neurosci. 2006, 31, 149-160.
17. Belmadani, A.; Tran, P.B.; Ren, D.; Miller, R.J. Chemokines regulate the migration of neural progenitors to sites of neuroinflammation. J. Neurosci. 2006, 26, 3182-3191.
18. Ziv, Y.; Avidan, H.; Pluchino, S.; Martino, G.; Schwartz, M. Synergy between immune cells and adult neural stem/progenitor cells promotes functional recovery from spinal cord injury. Proc. Natl. Acad. Sci. USA 2006, 103, 13174-13179.
19. Kerschensteiner, M.; Gallmeier, E.; Behrens, L.; Leal, V.V.; Misgeld, T.; Klinkert, W.E.; Kolbeck, R.; Hoppe, E.; Oropeza-Wekerle, R.L.; Bartke, I.; Stadelmann, C.; Lassmann, H.; Wekerle, H.; Hohlfeld, R. Activated human T cells, B cells, and monocytes produce brainderived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J. Exp. Med. 1999, 189, 865-870.
20. Burns, J.B.; Bartholomew, B.D.; Lobo, S.T. In vivo activation of myelin oligodendrocyte glycoprotein-specific T cells in healthy control subjects. Clin. Immunol. 2002, 105, 185-191.
21. Whitacre, C.C. Sex differences in autoimmune disease. Nat. Immunol. 2001, 2, 777-780.
22. Criswell, L.A.; Pfeiffer, K.A.; Lum, R.F.; Gonzales, B.; Novitzke, J.; Kern, M.; Moser, K.L.; Begovich, A.B.; Carlton, V.E.; Li, W.; Lee, A.T.; Ortmann, W.; Behrens, T.W.; Gregersen, P.K. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am. J. Hum. Genet. 2005, 76, 561-571.
23. Mackay, I.R.; Leskovsek, N.V.; Rose, N.R. Cell damage and autoimmunity: a critical appraisal. J. Autoimmun. 2008, 30, 5-11.
24. Ransohoff, R.M.; Kivisakk, P.; Kidd, G. Three or more routes for leukocyte migration into the central nervous system. Nat. Rev. Immunol. 2003, 3, 569-581.
25. Wekerle, H.; Sun, D.; Oropeza-Wekerle, R.L.; Meyermann, R. Immune reactivity in the nervous system: modulation of T-lymphocyte activation by glial cells. J. Exp. Biol. 1987, 132, 43-57.
26. Kivisakk, P.; Mahad, D.J.; Callahan, M.K.; Trebst, C.; Tucky, B.; Wei, T.; Wu, L.; Baekkevold, E.S.; Lassmann, H.; Staugaitis, S.M.; Campbell, J.J.; Ransohoff, R.M. Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc. Natl. Acad. Sci. USA 2003, 100, 8389-8394.
27. Hickey, W.F.; Hsu, B.L.; Kimura, H. T-lymphocyte entry into the central nervous system. J. Neurosci. Res. 1991, 28, 254-260.
28. Lassmann, H.; Wisniewski, H.M. Chronic relapsing EAE. Time course of neurological symptoms and pathology. Acta Neuropathol. 1978, 43, 35-42.
29. Kivisakk, P.; Imitola, J.; Rasmussen, S.; Elyaman, W.; Zhu, B.; Ransohoff, R.M.; Khoury, S.J. Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann. Neurol. 2009, 65, 457-469.
30. Reboldi, A.; Coisne, C.; Baumjohann, D.; Benvenuto, F.; Bottinelli, D.; Lira, S.; Uccelli, A.; Lanzavecchia, A.; Engelhardt, B.; Sallusto, F. C-C chemokine receptor 6-regulated entry of TH17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 2009, 10, 514-523.
31. Engelhardt, B. The blood-central nervous system barriers actively control immune cell entry into the central nervous system. Curr. Pharm. Des 2008, 14, 1555-1565.
32. Wu, C.; Ivars, F.; Anderson, P.; Hallmann, R.; Vestweber, D.; Nilsson, P.; Robenek, H.; Tryggvason, K.; Song, J.; Korpos, E.; Loser, K.; Beissert, S.; Georges-Labouesse, E.; Sorokin, L.M. Endothelial basement membrane laminin alpha5 selectively inhibits T lymphocyte extravasation into the brain. Nat. Med. 2009, 15, 519-527.
33. Agrawal, S.; Anderson, P.; Durbeej, M.; van Rooijen, N.; Ivars, F.; Opdenakker, G.; Sorokin, L.M. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J. Exp. Med. 2006, 203, 1007-1019.
34. Hickey, W.F.; Kimura, H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 1988, 239, 290-292.
35. Greter, M.; Heppner, F.L.; Lemos, M.P.; Odermatt, B.M.; Goebels, N.; Laufer, T.; Noelle, R.J.; Becher, B. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. 2005, 11, 328-334.
36. Kawakami, N.; Lassmann, S.; Li, Z.; Odoardi, F.; Ritter, T.; Ziemssen, T.; Klinkert, W.E.; Ellwart, J.W.; Bradl, M.; Krivacic, K.; Lassmann, H.; Ransohoff, R.M.; Volk, H.D.; Wekerle, H.; Linington, C.; Flugel, A. The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis. J. Exp. Med. 2004, 199, 185-197.
37. Galea, I.; Bernardes-Silva, M.; Forse, P.A.; van Rooijen, N.; Liblau, R.S.; Perry, V.H. An antigen-specific pathway for CD8 T cells across the blood-brain barrier. J. Exp. Med. 2007, 204, 2023-2030.
38. Kreutzberg, G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996, 19, 312-318.
39. Charcot, J. Histologie de la sclerose en plaques. Gazette des hopitaux (Paris) 1868, 41, 554-555.
40. Holmoy, T. A Norse contribution to the history of neurological diseases. Eur. Neurol. 2006, 55, 57-58.
41. Oksenberg, J.R.; Baranzini, S.E.; Sawcer, S.; Hauser, S.L. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat. Rev. Genet. 2008, 9, 516-526.
42. Ascherio, A.; Munger, K.L. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 2007, 61, 288-299.
43. Ascherio, A.; Munger, K.L. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann. Neurol. 2007, 61, 504-513.
44. McDonald, W.I.; Compston, A.; Edan, G.; Goodkin, D.; Hartung, H.P.; Lublin, F.D.; McFarland, H.F.; Paty, D.W.; Polman, C.H.; Reingold, S.C.; Sandberg-Wollheim, M.; Sibley, W.; Thompson, A.; Van Den Noort, S.; Weinshenker, B.Y.; Wolinsky, J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50, 121-127.
45. Thompson, A.J.; Polman, C.H.; Miller, D.H.; McDonald, W.I.; Brochet, B.; Filippi, M.; Montalban, X; De, S.J. Primary progressive multiple sclerosis. Brain 1997, 120 (Pt 6), 1085-1096.
46. Weinshenker, B.G.; Bass, B.; Rice, G.P.; Noseworthy, J.; Carriere, W.; Baskerville, J.; Ebers, G.C. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989, 112 (Pt 1), 133-146.
47. Lincoln, M.R.; Montpetit, A.; Cader, M.Z.; Saarela, J.; Dyment, D.A.; Tiislar, M.; Ferretti, V.; Tienari, P.J.; Sadovnick, A.D.; Peltonen, L.; Ebers, G.C.; Hudson, T.J. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat. Genet. 2005, 37, 1108-1112.
48. Svejgaard, A. The immunogenetics of multiple sclerosis. Immunogenetics 2008, 60, 275-286.
49. Hafler, D.A.; Compston, A.; Sawcer, S.; Lander, E.S.; Daly, M.J.; De Jager, P.L.; de Bakker, P.I.; Gabriel, S.B.; Mirel, D.B.; Ivinson, A.J.; Pericak-Vance, M.A.; Gregory, S.G.; Rioux, J.D.; McCauley, J.L.; Haines, J.L.; Barcellos, L.F.; Cree, B.; Oksenberg, J.R.; Hauser, S.L. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 2007, 357, 851-862.
50. Lundmark, F.; Duvefelt, K.; Iacobaeus, E.; Kockum, I.; Wallstrom, E.; Khademi, M.; Oturai, A.; Ryder, L.P.; Saarela, J.; Harbo, H.F.; Celius, E.G.; Salter, H.; Olsson, T.; Hillert, J. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat. Genet. 2007, 39, 1108-1113.
51. Ebers, G.C.; Sadovnick, A.D.; Risch, N.J. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 1995, 377, 150-151.
52. Ascherio, A.; Munger, K.L.; Lennette, E.T.; Spiegelman, D.; Hernan, M.A.; Olek, M.J.; Hankinson, S.E.; Hunter, D.J. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001, 286, 3083-3088.
53. Lunemann, J.D.; Edwards, N.; Muraro, P.A.; Hayashi, S.; Cohen, J.I.; Munz, C.; Martin, R. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 2006, 129, 1493-1506.
54. Lang, H.L.; Jacobsen, H.; Ikemizu, S.; Andersson, C.; Harlos, K.; Madsen, L.; Hjorth, P.; Sondergaard, L.; Svejgaard, A.; Wucherpfennig, K.; Stuart, D.I.; Bell, J.I.; Jones, E.Y.; Fugger, L. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. Immunol. 2002, 3, 940-943.
55. Holmoy, T.; Kvale, E.O.; Vartdal, F. Cerebrospinal fluid CD4 T cells from a multiple sclerosis patient cross-recognize Epstein-Barr virus and myelin basic protein. J. Neurovirol. 2004, 10, 278-283.
56. Jilek, S.; Schluep, M.; Meylan, P.; Vingerhoets, F.; Guignard, L.; Monney, A.; Kleeberg, J.; Le, G.G.; Pantaleo, G.; Du Pasquier, R.A. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 2008, 131, 1712-1721.
57. Serafini, B.; Rosicarelli, B.; Franciotta, D.; Magliozzi, R.; Reynolds, R.; Cinque, P.; Andreoni, L.; Trivedi, P.; Salvetti, M.; Faggioni, A.; Aloisi, F. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 2007, 204, 2899-2912.
58. Sargsyan, S.A.; Shearer, A.J.; Ritchie, A.M.; Burgoon, M.P.; Anderson, S.; Hemmer, B.; Stadelmann, C.; Gattenlohner, S.; Owens, G.P.; Gilden, D.; Bennett, J.L. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology2010, 74, 1127-1135.
59. Willis, S.N.; Stadelmann, C.; Rodig, S.J.; Caron, T.; Gattenloehner, S.; Mallozzi, S.S.; Roughan, J.E.; Almendinger, S.E.; Blewett, M.M.; Bruck, W.; Hafler, D.A.; O'Connor, K.C. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain2009, 132, 3318-3328.
60. Steinman, L. Multiple sclerosis: a two-stage disease. Nat. Immunol. 2001, 2, 762-764.
61. Holmoy, T. Immunopathogenesis of multiple sclerosis: concepts and controversies. Acta Neurol. Scand. 2007, 187 (Suppl.), 39-45.
62. Polman, C.H.; O'Connor, P.W.; Havrdova, E.; Hutchinson, M.; Kappos, L.; Miller, D.H.; Phillips, J.T.; Lublin, F.D.; Giovannoni, G.; Wajgt, A.; Toal, M.; Lynn, F.; Panzara, M.A.; Sandrock, A.W. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 354, 899-910.
63. Coles, A.J.; Compston, D.A.; Selmaj, K.W.; Lake, S.L.; Moran, S.; Margolin, D.H.; Norris, K.; Tandon, P.K. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 2008, 359, 1786-1801.
64. McFarland, H.F.; Martin, R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 2007, 8, 913-919.
65. Holmoy, T.; Vandvik, B.; Vartdal, F. T cells from multiple sclerosis patients recognize immunoglobulin G from cerebrospinal fluid. Mult. Scler. 2003, 9, 228-234.
66. Breij, E.C.; Brink, B.P.; Veerhuis, R.; van den Berg, C.; Vloet, R.; Yan, R.; Dijkstra, C.D.; van der Valk, P.; Bo, L. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann. Neurol. 2008, 63, 16-25.
67. Barnett, M.H.; Sutton, I. The pathology of multiple sclerosis: a paradigm shift. Curr. Opin. Neurol. 2006, 19, 242-247.
68. Chard, D.; Miller, D. Grey matter pathology in clinically early multiple sclerosis: evidence from magnetic resonance imaging. J. Neurol. Sci. 2009, 282, 5-11.
69. Trapp, B.D.; Peterson, J.; Ransohoff, R.M.; Rudick, R.; Mork, S.; Bo, L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338, 278-285.
70. Skulina, C.; Schmidt, S.; Dornmair, K.; Babbe, H.; Roers, A.; Rajewsky, K.; Wekerle, H.; Hohlfeld, R.; Goebels, N. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc. Natl. Acad. Sci. USA2004,101, 2428-2433.
71. Junker, A.; Ivanidze, J.; Malotka, J.; Eiglmeier, I.; Lassmann, H.; Wekerle, H.; Meinl, E.; Hohlfeld, R.; Dornmair, K. Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain 2007, 130, 2789-2799.
72. Tzartos, J.S.; Friese, M.A.; Craner, M.J.; Palace, J.; Newcombe, J.; Esiri, M.M.; Fugger, L. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 2008, 172, 146-155.
73. Kebir, H.; Kreymborg, K.; Ifergan, I.; Dodelet-Devillers, A.; Cayrol, R.; Bernard, M.; Giuliani, F.; Arbour, N.; Becher, B.; Prat, A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 2007, 13, 1173-1175.
74. Steinman, L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med. 2007, 13, 139-145.
75. Oksenberg, J.R.; Stuart, S.; Begovich, A.B.; Bell, R.B.; Erlich, H.A.; Steinman, L.; Bernard, C.C. Limited heterogeneity of rearranged T-cell receptor V alpha transcripts in brains of multiple sclerosis patients. Nature 1990, 345, 344-346.
76. Wucherpfennig, K.W.; Newcombe, J.; Li, H.; Keddy, C.; Cuzner, M.L.; Hafler, D.A. T cell receptor V alpha-V beta repertoire and cytokine gene expression in active multiple sclerosis lesions. J. Exp. Med. 1992, 175, 993-1002.
77. Kivisakk, P.; Mahad, D.J.; Callahan, M.K.; Sikora, K.; Trebst, C.; Tucky, B.; Wujek, J.; Ravid, R.; Staugaitis, S.M.; Lassmann, H.; Ransohoff, R.M. Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann. Neurol. 2004, 55, 627-638.
78. Bar-Or, A. The immunology of multiple sclerosis. Semin. Neurol. 2008, 28, 29-45.
79. Bielekova, B.; Goodwin, B.; Richert, N.; Cortese, I.; Kondo, T.; Afshar, G.; Gran, B.; Eaton, J.; Antel, J.; Frank, J.A.; McFarland, H.F.; Martin, R. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 2000, 6, 1167-1175.
80. Montes, M.; Zhang, X.; Berthelot, L.; Laplaud, D.A.; Brouard, S.; Jin, J.; Rogan, S.; Armao, D.; Jewells, V.; Soulillou, J.P.; Markovic-Plese, S. Oligoclonal myelin-reactive T-cell infiltrates derived from multiple sclerosis lesions are enriched in Th17 cells. Clin. Immunol. 2009, 130, 133-144.
81. Hafler, D.A.; Benjamin, D.S.; Burks, J.; Weiner, H.L. Myelin basic protein and proteolipid protein reactivity of brain- and cerebrospinal fluid-derived T cell clones in multiple sclerosis and postinfectious encephalomyelitis. J. Immunol. 1987, 139, 68-72.
82. Schwartz, M.; Ziv, Y. Immunity to self and self-maintenance: a unified theory of brain pathologies. Trends Immunol. 2008, 29, 211-219.
83. van Noort, J.M.; van Sechel, A.C.; Bajramovic, J.J.; El Ouagmiri, M.; Polman, C.H.; Lassmann, H.; Ravid, R. The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature 1995, 375, 798-801.
84. Chabas, D.; Baranzini, S.E.; Mitchell, D.; Bernard, C.C.; Rittling, S.R.; Denhardt, D.T.; Sobel, R.A.; Lock, C.; Karpuj, M.; Pedotti, R.; Heller, R.; Oksenberg, J.R.; Steinman, L. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001, 294, 1731-1735.
85. Steinman, L. New targets for treatment of multiple sclerosis. J. Neurol. Sci. 2008, 274, 1-4.
86. Torkildsen, O.; Stansberg, C.; Angelskar, S.M.; Kooi, E.J.; Geurts, J.J.; van der Valk, V; Myhr, K.M.; Steen, V.M.; Bo, L. Upregulation of Immunoglobulin-related Genes in Cortical Sections from Multiple Sclerosis Patients. Brain Pathol. 2009, doi:10.1111/j.1750-3639.2009.00343.x.
87. Storch, M.K.; Piddlesden, S.; Haltia, M.; Iivanainen, M.; Morgan, P.; Lassmann, H. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann. Neurol. 1998, 43, 465-471.
88. Vandvik, B.; Vartdal, F.; Norrby, E. Herpes simplex virus encephalitis: intrathecal synthesis of oligoclonal virus-specific IgG, IgA and IgM antibodies. J. Neurol. 1982, 228, 25-38.
89. Vartdal, F.; Vandvik, B.; Norrby, E. Intrathecal synthesis of virus-specific oligoclonal IgG, IgA and IgM antibodies in a case of varicella-zoster meningoencephalitis. J. Neurol. Sci. 1982, 57, 121-132.
90. McLaughlin, K.A.; Wucherpfennig, K.W. B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv. Immunol. 2008, 98, 121-149.
91. Qin, Y.; Duquette, P.; Zhang, Y.; Olek, M.; Da, R.R.; Richardson, J.; Antel, J.P.; Talbot, P.; Cashman, N.R.; Tourtellotte, W.W.; Wekerle, H.; van Den Noort, S. Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis. Lab. Invest. 2003, 83, 1081-1088.
92. Monson, N.L.; Brezinschek, H.P.; Brezinschek, R.I.; Mobley, A.; Vaughan, G.K.; Frohman, E.M.; Racke, M.K.; Lipsky, P.E. Receptor revision and atypical mutational characteristics in clonally expanded B cells from the cerebrospinal fluid of recently diagnosed multiple sclerosis patients. J. Neuroimmunol. 2005, 158, 170-181.
93. Owens, G.P.; Winges, K.M.; Ritchie, A.M.; Edwards, S.; Burgoon, M.P.; Lehnhoff, L.; Nielsen, K.; Corboy, J.; Gilden, D.H.; Bennett, J.L. VH4 gene segments dominate the intrathecal humoral immune response in multiple sclerosis. J. Immunol. 2007, 179, 6343-6351.
94. Cepok, S.; Rosche, B.; Grummel, V.; Vogel, F.; Zhou, D.; Sayn, J.; Sommer, N.; Hartung, H.P.; Hemmer, B. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005, 128, 1667-1676.
95. Obermeier, B.; Mentele, R.; Malotka, J.; Kellermann, J.; Kumpfel, T.; Wekerle, H.; Lottspeich, F.; Hohlfeld, R.; Dornmair, K. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat. Med. 2008, 14, 688-693.
96. Owens, G.P.; Bennett, J.L.; Gilden, D.H.; Burgoon, M.P. The B cell response in multiple sclerosis. Neurol. Res. 2006, 28, 236-244.
97. O'Connor, K.C.; Chitnis, T.; Griffin, D.E.; Piyasirisilp, S.; Bar-Or, A.; Khoury, S.; Wucherpfennig, K.W.; Hafler, D.A. Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J. Neuroimmunol. 2003, 136, 140-148.
98. Martino, G.; Olsson, T.; Fredrikson, S.; Hojeberg, B.; Kostulas, V.; Grimaldi, L.M.; Link, H. Cells producing antibodies specific for myelin basic protein region 70-89 are predominant in cerebrospinal fluid from patients with multiple sclerosis. Eur. J. Immunol. 1991, 21, 2971-2976.
99. O'Connor, K.C.; Appel, H.; Bregoli, L.; Call, M.E.; Catz, I.; Chan, J.A.; Moore, N.H.; Warren, K.G.; Wong, S.J.; Hafler, D.A.; Wucherpfennig, K.W. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J. Immunol. 2005, 175, 1974-1982.
100. Lambracht-Washington, D.; O'Connor, K.C.; Cameron, E.M.; Jowdry, A.; Ward, E.S.; Frohman, E.; Racke, M.K.; Monson, N.L. Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS. J. Neuroimmunol. 2007, 186, 164-176.
101. Vartdal, F.; Vandvik, B.; Norrby, E. Viral and bacterial antibody responses in multiple sclerosis. Ann. Neurol. 1980, 8, 248-255.
102. Luxton, R.W.; Zeman, A.; Holzel, H.; Harvey, P.; Wilson, J.; Kocen, R.; Morgan-Hughes, J.; Miller, D.H.; Compston, A.; Thompson, E.J. Affinity of antigen-specific IgG distinguishes multiple sclerosis from encephalitis. J. Neurol. Sci. 1995, 132, 11-19.
103. Vartdal, F.; Vandvik, B. Multiple sclerosis. Electrofocused bands of oligoclonal CSF IgG do not carry antibody activity against measles, varicella-zoster or rotaviruses. J. Neurol. Sci. 1982, 54, 99-107.
104. Sindic, C.J.; Monteyne, P.; Laterre, E.C. The intrathecal synthesis of virus-specific oligoclonal IgG in multiple sclerosis. J. Neuroimmunol. 1994, 54, 75-80.
105. Vartdal, F.; Vandvik, B. Multiple sclerosis: subclasses of intrathecally synthesized IgG and measles and varicella zoster virus IgG antibodies. Clin. Exp. Immunol. 1983, 54, 641-647.
106. Robinson-Agramonte, M.; Reiber, H.; Cabrera-Gomez, J.A.; Galvizu, R. Intrathecal polyspecific immune response to neurotropic viruses in multiple sclerosis: a comparative report from Cuban patients. Acta Neurol. Scand. 2007, 115, 312-318.
107. Skorstad, G.; Vandvik, B.; Vartdal, F.; Holmoy, T. MS and clinically isolated syndromes: Shared specificity but diverging clonal patterns of virus-specific IgG antibodies produced in vivo and by CSF B cells in vitro. Eur. J. Neurol. 2009, 16, 1124-1129.
108. Serafini, B.; Rosicarelli, B.; Magliozzi, R.; Stigliano, E.; Aloisi, F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004, 14, 164-174.
109. Hjelmstrom, P. Lymphoid neogenesis: de novo formation of lymphoid tissue in chronic inflammation through expression of homing chemokines. J. Leukoc. Biol. 2001, 69, 331-339.
110. Corcione, A.; Casazza, S.; Ferretti, E.; Giunti, D.; Zappia, E.; Pistorio, A.; Gambini, C.; Mancardi, G.L.; Uccelli, A.; Pistoia, V. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc. Natl. Acad. Sci. USA 2004, 101, 11064-11069.
111. Hauser, S.L.; Waubant, E.; Arnold, D.L.; Vollmer, T.; Antel, J.; Fox, R.J.; Bar-Or, A.; Panzara, M.; Sarkar, N.; Agarwal, S.; Langer-Gould, A.; Smith, C.H. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358, 676-688.
112. Cross, A.H.; Stark, J.L.; Lauber, J.; Ramsbottom, M.J.; Lyons, J.A. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 2006, 180, 63-70.
113. Holmoy, T.; Vartdal, F. The immunological basis for treatment of multiple sclerosis. Scand. J. Immunol. 2007, 66, 374-382.
114. Teitelbaum, D.; Meshorer, A.; Hirshfeld, T.; Arnon, R.; Sela, M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1971, 1, 242-248.
115. Johnson, K.P.; Brooks, B.R.; Cohen, J.A.; Ford, C.C.; Goldstein, J.; Lisak, R.P.; Myers, L.W.; Panitch, H.S.; Rose, J.W.; Schiffer, R.B. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995, 45, 1268-1276.
116. Johnson, K.P.; Brooks, B.R.; Cohen, J.A.; Ford, C.C.; Goldstein, J.; Lisak, R.P.; Myers, L.W.; Panitch, H.S.; Rose, J.W.; Schiffer, R.B.; Vollmer, T.; Weiner, L.P.; Wolinsky, J.S. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998, 50, 701-708.
117. Fridkis-Hareli, M.; Strominger, J.L. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J. Immunol. 1998, 160, 4386-4397.
118. Schrempf, W.; Ziemssen, T. Glatiramer acetate: mechanisms of action in multiple sclerosis. Autoimmun. Rev. 2007, 6, 469-475.
119. Hestvik, A.L.; Skorstad, G.; Price, D.A.; Vartdal, F.; Holmoy, T. Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid. Mult. Scler. 2008, 14, 749-758.
120. Duda, P.W.; Schmied, M.C.; Cook, S.L.; Krieger, J.I.; Hafler, D.A. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest 2000, 105, 967-976.
121. Neuhaus, O.; Farina, C.; Yassouridis, A.; Wiendl, H.; Then, B.F.; Dose, T.; Wekerle, H.; Hohlfeld, R. Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc. Natl. Acad. Sci. USA 2000, 97, 7452-7457.
122. Ragheb, S.; Abramczyk, S.; Lisak, D.; Lisak, R. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells. Mult. Scler. 2001, 7, 43-47.
123. Chen, M.; Conway, K.; Johnson, K.P.; Martin, R.; Dhib-Jalbut, S. Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J. Neurol. Sci. 2002, 201, 71-77.
124. Farina, C.; Then, B.F.; Albrecht, H.; Meinl, E.; Yassouridis, A.; Neuhaus, O.; Hohlfeld, R. Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain 2001, 124, 705-719.
125. Karandikar, N.J.; Crawford, M.P.; Yan, X.; Ratts, R.B.; Brenchley, J.M.; Ambrozak, D.R.; Lovett-Racke, A.E.; Frohman, E.M.; Stastny, P.; Douek, D.C.; Koup, R.A.; Racke, M.K. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J. Clin. Invest. 2002, 109, 641-649.
126. Aharoni, R.; Kayhan, B.; Eilam, R.; Sela, M.; Arnon, R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc. Natl. Acad. Sci. USA 2003, 100, 14157-14162.
127. Dressel, A.; Vogelgesang, A.; Brinkmeier, H.; Mader, M.; Weber, F. Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment. J. Neuroimmunol. 2006, 181, 133-140.
128. Sand, K.L.; Knudsen, E.; Rolin, J.; Al-Falahi, Y.; Maghazachi, A.A. Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate. Cell Mol. Life Sci. 2009, 66, 1446-1456.
129. Kala, M.; Rhodes, S.N.; Piao, W.H.; Shi, F.D.; Campagnolo, D.I.; Vollmer, T.L. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp. Neurol. 2010, 221, 136-145.
130. Aharoni, R.; Meshorer, A.; Sela, M.; Arnon, R. Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system. J. Neuroimmunol. 2002, 126, 58-68.
131. Aharoni, R.; Teitelbaum, D.; Leitner, O.; Meshorer, A.; Sela, M.; Arnon, R. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc. Natl. Acad. Sci. USA 2000, 97, 11472-11477.
132. Aharoni, R.; Teitelbaum, D.; Sela, M.; Arnon, R. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 1997, 94, 10821-10826.
133. Aharoni, R.; Teitelbaum, D.; Arnon, R.; Sela, M. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc. Natl. Acad. Sci. USA 1999, 96, 634-639.
134. Teitelbaum, D.; Fridkis-Hareli, M.; Arnon, R.; Sela, M. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J. Neuroimmunol. 1996, 64, 209-217.
135. Ben-Nun, A.; Mendel, I.; Bakimer, R.; Fridkis-Hareli, M.; Teitelbaum, D.; Arnon, R.; Sela, M.; Kerlero de, R.N. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease. J. Neurol. 1996, 243, S14-S22.
136. Burns, J.; Krasner, L.J.; Guerrero, F. Human cellular immune response to copolymer I and myelin basic protein. Neurology 1986, 36, 92-94.
137. Dabbert, D.; Rosner, S.; Kramer, M.; Scholl, U.; Tumani, H.; Mader, M.; Weber, F. Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein. Neurosci. Lett. 2000, 289, 205-208.
138. Gran, B.; Tranquill, L.R.; Chen, M.; Bielekova, B.; Zhou, W.; Dhib-Jalbut, S.; Martin, R. Mechanisms of immunomodulation by glatiramer acetate. Neurology 2000, 55, 1704-1714.
139. Chen, M.; Gran, B.; Costello, K.; Johnson, K.; Martin, R.; Dhib-Jalbut, S. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult. Scler. 2001, 7, 209-219.
140. Arnon, R.; Aharoni, R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc. Natl. Acad. Sci. USA 2004, 101 (Suppl 2), 14593-14598.
141. Zhang, M.; Chan, C.C.; Vistica, B.; Hung, V.; Wiggert, B.; Gery, I. Copolymer 1 inhibits experimental autoimmune uveoretinitis. J. Neuroimmunol. 2000, 103, 189-194.
142. Aharoni, R.; Arnon, R.; Eilam, R. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J. Neurosci. 2005, 25, 8217-8228.
143. Ziemssen, T.; Kumpfel, T.; Klinkert, W.E.; Neuhaus, O.; Hohlfeld, R. Glatiramer acetate- specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 2002, 125, 2381-2391.
144. Chen, M.; Valenzuela, R.M.; Dhib-Jalbut, S. Glatiramer acetate-reactive T cells produce brain- derived neurotrophic factor. J. Neurol. Sci. 2003, 215, 37-44.
145. Aharoni, R.; Eilam, R.; Domev, H.; Labunskay, G.; Sela, M.; Arnon, R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc. Natl. Acad. Sci. USA 2005, 102, 19045-19050.
146. Skihar, V.; Silva, C.; Chojnacki, A.; Doring, A.; Stallcup, W.B.; Weiss, S.; Yong, V.W. Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate. Proc. Natl. Acad. Sci. USA 2009, 106, 17992-17997.
147. Aharoni, R.; Herschkovitz, A.; Eilam, R.; Blumberg-Hazan, M.; Sela, M.; Bruck, W.; Arnon, R. Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 2008, 105, 11358-11363.
148. Angelov, D.N.; Waibel, S.; Guntinas-Lichius, O.; Lenzen, M.; Neiss, W.F.; Tomov, T.L.; Yoles, E.; Kipnis, J.; Schori, H.; Reuter, A.; Ludolph, A.; Schwartz, M. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 2003, 100, 4790-4795.
149. Banerjee, R.; Mosley, R.L.; Reynolds, A.D.; Dhar, A.; Jackson-Lewis, V.; Gordon, P.H.; Przedborski, S.; Gendelman, H.E. Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS. ONE 2008, 3, e2740.
150. Weber, M.S.; Hohlfeld, R.; Zamvil, S.S. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 2007, 4, 647-653.